دورية أكاديمية
أعرض في EDS

Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma.
المؤلفون: Son JA; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea., Weon JH; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea., Baek GO; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea., Ahn HR; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea., Choi JY; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea., Yoon MG; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea., Cho HJ; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea., Cheong JY; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea., Eun JW; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea. jetaimebin@gmail.com., Kim SS; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea. cocorico99@gmail.com.
المصدر: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Oct 30; Vol. 42 (1), pp. 288. Date of Electronic Publication: 2023 Oct 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Publication: 2009- : London : BioMed Central
Original Publication: [Roma] : APSIT,
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/diagnosis , Carcinoma, Hepatocellular*/genetics , Carcinoma, Hepatocellular*/metabolism , Liver Neoplasms*/diagnosis , Liver Neoplasms*/genetics , Liver Neoplasms*/metabolism , Extracellular Vesicles*/genetics , Extracellular Vesicles*/metabolism, Humans ; alpha-Fetoproteins/metabolism ; Biomarkers, Tumor/metabolism ; RNA Splicing Factors/genetics ; RNA Splicing Factors/metabolism ; Autoantibodies/metabolism
مستخلص: Background: Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer cases and related deaths. The purpose of this study was to assess the diagnostic value of splicing factor 3b subunit 4 (SF3B4) as a novel non-invasive biomarker for HCC and determine the association between SF3B4 expression and immune cell infiltration.
Methods: An enzyme-linked immunosorbent assay (ELISA) was used to detect SF3B4 levels in plasma samples obtained from healthy controls (HCs) and patients with chronic hepatitis, liver cirrhosis, and HCC. The expression levels of autoantibodies that detect SF3B4 in the plasma samples of each group of patients were measured. Small extracellular vesicles (EVs) were isolated from patient sera, and the expression levels of EV-SF3B4 were measured using quantitative reverse transcription PCR.
Results: ELISA results confirmed that the expression levels of SF3B4 proteins and autoantibodies in the plasma of patients with HCC were higher than those in HCs. However, their diagnostic performance was not better than that of alpha-fetoprotein (AFP). The mRNA expression of SF3B4 in serum EV increased but not in the buffy coat or serum of patients with HCC. Serum EV-SF3B4 displayed better diagnostic power than AFP for all stages of HCC (AUC = 0.968 vs. 0.816), including early-stage HCC (AUC = 0.960 vs. 0.842), and this was consistent in the external cohort. Single-cell RNA sequencing indicated that SF3B4 expression was correlated with myeloid-derived suppressor cells. The Tumor Immune Estimation Resource database reconfirmed the correlation between SF3B4 expression and immune cell infiltration in HCC.
Conclusions: SF3B4 may be associated with tumor immune infiltration in HCC, and EV-SF3B4 shows potential as a novel non-invasive diagnostic biomarker of HCC.
(© 2023. The Author(s).)
References: Hepatology. 2003 May;37(5):1114-21. (PMID: 12717392)
Clin Breast Cancer. 2017 Jun;17(3):e151-e153. (PMID: 28139434)
Cancer Genet Cytogenet. 2007 May;175(1):73-6. (PMID: 17498563)
J Immunol. 2013 Apr 1;190(7):3783-97. (PMID: 23440412)
Hepatology. 2021 Jan;73(1):422-436. (PMID: 32017145)
EBioMedicine. 2018 Dec;38:57-68. (PMID: 30391496)
Nat Cancer. 2021 Dec;2(12):1287. (PMID: 35121911)
Protein Cell. 2022 Aug;13(8):559-579. (PMID: 34196950)
Discov Med. 2021 Nov-Dec;32(167):123-132. (PMID: 35220998)
Hepatology. 2018 Aug;68(2):723-750. (PMID: 29624699)
Anticancer Res. 2020 May;40(5):2941-2946. (PMID: 32366446)
Tumour Biol. 2017 Mar;39(3):1010428317695913. (PMID: 28351319)
Liver Int. 2022 Aug;42(9):2029-2041. (PMID: 35319165)
J Leukoc Biol. 2014 Nov;96(5):685-93. (PMID: 24929004)
Aging (Albany NY). 2019 Dec 6;11(23):11157-11169. (PMID: 31811111)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Aliment Pharmacol Ther. 2009 Jul;30(1):37-47. (PMID: 19392863)
Front Pharmacol. 2018 Jun 11;9:612. (PMID: 29942258)
Anticancer Res. 2020 Apr;40(4):2033-2042. (PMID: 32234894)
Hepatology. 2018 Apr;67(4):1360-1377. (PMID: 29059470)
J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281)
J Hepatol. 2012 Jun;56(6):1371-83. (PMID: 22314424)
Hepatology. 2019 Mar;69(3):1180-1192. (PMID: 30168613)
Cell Death Dis. 2022 Feb 24;13(2):179. (PMID: 35210412)
Anticancer Res. 2016 May;36(5):2139-44. (PMID: 27127115)
Oncoscience. 2018 Aug 22;5(7-8):209-211. (PMID: 30234139)
Lancet. 2022 Oct 15;400(10360):1345-1362. (PMID: 36084663)
Clin Gastroenterol Hepatol. 2007 Mar;5(3):394-402; quiz 267. (PMID: 17368240)
معلومات مُعتمدة: HR21C1003 Korea National Institute of Health; HR22C1734 Korea National Institute of Health; NRF-2022R1H1A2093189 National Research Foundation of Korea; NRF-2022R1A2C2092422 National Research Foundation of Korea; NRF-2022M3A9G101451421 National Research Foundation of Korea; NRF-2021R1C1C1009619 National Research Foundation of Korea
فهرسة مساهمة: Keywords: Biomarker; Liquid biopsy; Liver Neoplasms; Myeloid-derived suppressor cell; SF3B4
المشرفين على المادة: 0 (alpha-Fetoproteins)
0 (Biomarkers, Tumor)
0 (RNA Splicing Factors)
0 (Autoantibodies)
0 (SF3B4 protein, human)
تواريخ الأحداث: Date Created: 20231030 Date Completed: 20231031 Latest Revision: 20231101
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10614366
DOI: 10.1186/s13046-023-02867-y
PMID: 37899451
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا